FCGBP

FCGBP is a very large mucin-like protein secreted by goblet and other mucin-producing epithelial cells at mucosal surfaces, where it functions in mucosal immune defense (PMID:9182547, PMID:12117874). Its N-terminal 450 amino acids are necessary and sufficient to confer IgG Fc binding activity, and the protein is built from repeated ~400-amino acid cysteine-rich units containing a CGLCGN motif shared with the mucins MUC2 and von Willebrand factor (PMID:9182547). FCGBP is expressed in mucin-secreting cells across the colon, small intestine, gall bladder, biliary tract, bronchus, submandibular gland, and cervix, is released into their secreted fluids and the gut lumen with retained IgG-binding activity, and suppresses complement-mediated haemolysis in vitro (PMID:12117874, PMID:16097391). Loss-of-function in human vascular fibroblasts and Fcgbp-knockdown mice destabilizes the vascular wall and increases vascular injury, indicating an additional role in vascular wall integrity [PMID:bio_10.1101_2024.08.06.24311443]. Beyond these activities, the molecular details of how FCGBP traffics or organizes IgG within mucus have not been further characterized in the available corpus.

1. 1991 Low

   Before FCGBP was molecularly defined, an early question was whether a discrete human protein could bind IgG Fc independently of classical Fc receptors; an interferon-inducible intracellular IgG-binding phosphoprotein was characterized, though it is likely distinct from the large secretory FCGBP later cloned.

   Evidence Immunoprecipitation from radiolabeled cells, surface binding and phosphorylation analysis in human cells

   PMID:1825221

   Open questions at the time

   • The ~45–50 kDa intracellular IFN-induced protein may not be the canonical secretory FCGBP locus
   • No sequence or gene assignment linking it to the cloned FCGBP
2. 1997 High

   The question of which region of FCGBP mediates IgG binding and how the protein is organized was resolved by cloning, mapping the IgG Fc binding activity to the N-terminal 450 residues and revealing a repetitive mucin-like cysteine-rich architecture.

   Evidence cDNA cloning, sequence analysis, and domain deletion/expression binding assay

   PMID:9182547

   Open questions at the time

   • No structure of the IgG-binding domain
   • Affinity and stoichiometry of IgG binding not quantified
   • Functional consequence of the mucin-like repeats untested
3. 1997 Low

   Whether FCGBP-bound IgG could be detected in circulation as a marker of secretory activity was addressed by detecting elevated serum FCGBP antigen in autoimmune disease patients.

   Evidence ELISA and immunoprecipitation on patient sera

   PMID:11600203

   Open questions at the time

   • Single immunoassay, no mechanistic dissection
   • Causal link to autoimmune pathology not established
4. 2002 Medium

   To establish where FCGBP acts and whether secreted FCGBP retains function, its expression across mucosal epithelia and a complement-suppressing activity were demonstrated.

   Evidence Immunohistochemistry, immunoprecipitation, and complement-mediated haemolysis inhibition assay across multiple human tissues

   PMID:12117874

   Open questions at the time

   • Mechanism of complement suppression unresolved
   • Whether IgG binding and complement suppression are coupled untested
5. 2005 Medium

   The question of whether FCGBP is genuinely secreted into the mucosal lumen rather than retained intracellularly was answered by identifying it as an abundant faecal protein.

   Evidence 2D gel electrophoresis and MALDI-TOF mass spectrometry of mouse stool

   PMID:16097391

   Open questions at the time

   • No functional readout in the luminal compartment
   • Relationship to mucus structure not examined
6. 2020 Medium

   FCGBP expression was linked to a specific epithelial cell-fate decision, marking metaplastic respiratory cells arising from exhausted olfactory stem cells.

   Evidence In vivo mouse genetic models with lineage tracing and immunofluorescence

   PMID:32385093

   Open questions at the time

   • FCGBP used as a fate marker, not functionally dissected
   • No test of whether FCGBP affects the metaplastic phenotype
7. 2024 Medium

   Whether FCGBP has a role beyond mucosal immunity was addressed by loss-of-function studies implicating it in vascular wall stability and acute pancreatitis severity.

   Evidence Whole-exome sequencing, serum ELISA, Fcgbp-knockdown mice, and FCGBP-knockdown human vascular fibroblasts (preprint)

   PMID:bio_10.1101_2024.08.06.24311443

   Open questions at the time

   • Molecular mechanism of vascular stabilization unknown
   • Not yet peer-reviewed
   • Connection between vascular role and mucosal/IgG-binding function unclear

• How FCGBP molecularly transports or sequesters IgG within mucus, and how its mucin-like repeats and any covalent linkages organize the mucus barrier, remains unresolved.
• No structural model of the IgG-binding domain
• No defined biochemical mechanism for complement suppression
• Mechanism linking FCGBP to vascular integrity uncharacterized